{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:41:22Z","timestamp":1761896482509},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2017,1,20]],"date-time":"2017-01-20T00:00:00Z","timestamp":1484870400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100014207","name":"National Public Health Grand Research Foundation","doi-asserted-by":"crossref","award":["201202017"],"award-info":[{"award-number":["201202017"]}],"id":[{"id":"10.13039\/501100014207","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Zhejiang Province Funding for Distinguished Young Scholars","award":["LR12H08001"],"award-info":[{"award-number":["LR12H08001"]}]},{"DOI":"10.13039\/501100001809","name":"the National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["No.81270582"],"award-info":[{"award-number":["No.81270582"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Major Program of Science Technology Department of Zhejiang Province Fund","award":["2013C03043-2"],"award-info":[{"award-number":["2013C03043-2"]}]},{"name":"the Foundation of Innovation Team for Basic and Clinical Research of Zhejiang Province","award":["2011R50015"],"award-info":[{"award-number":["2011R50015"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China grants","doi-asserted-by":"crossref","award":["30870914"],"award-info":[{"award-number":["30870914"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China grants","doi-asserted-by":"crossref","award":["81470290"],"award-info":[{"award-number":["81470290"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"The National Key Technology R and D Program","award":["2014BAI09B13"],"award-info":[{"award-number":["2014BAI09B13"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"published-print":{"date-parts":[[2017,5]]},"DOI":"10.1007\/s00432-016-2331-0","type":"journal-article","created":{"date-parts":[[2017,1,20]],"date-time":"2017-01-20T08:33:35Z","timestamp":1484901215000},"page":"873-882","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Decitabine priming prior to low-dose chemotherapy improves patient outcomes in myelodysplastic syndromes-RAEB: a retrospective analysis vs. chemotherapy alone"],"prefix":"10.1007","volume":"143","author":[{"given":"Li","family":"Ye","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanling","family":"Ren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinping","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chen","family":"Mei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liya","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xingnong","family":"Ye","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juying","family":"Wei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weilai","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haitao","family":"Meng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenbin","family":"Qian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenyuan","family":"Mai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yinjun","family":"Lou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gaixiang","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiejing","family":"Qian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yejiang","family":"Lou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yingwan","family":"Luo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lili","family":"Xie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peipei","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chao","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jie","family":"Jin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongyan","family":"Tong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,1,20]]},"reference":[{"key":"2331_CR1","doi-asserted-by":"publisher","first-page":"2239","DOI":"10.1016\/S0140-6736(13)61901-7","volume":"383","author":"L Ades","year":"2014","unstructured":"Ades L, Itzykson R, Fenaux P (2014) Myelodysplastic syndromes. Lancet 383:2239\u20132252. doi: 10.1016\/S0140-6736(13)61901-7","journal-title":"Lancet"},{"key":"2331_CR2","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.7314\/APJCP.2014.15.3.1247","volume":"15","author":"F Ahmad","year":"2014","unstructured":"Ahmad F, Mohota R, Sanap S, Mandava S, Das BR (2014) Molecular evaluation of DNMT3A and IDH1\/2 gene mutation: frequency, distribution pattern and associations with additional molecular markers in normal karyotype Indian acute myeloid leukemia patients. Asian Pac J Cancer Prev 15:1247\u20131253","journal-title":"Asian Pac J Cancer Prev"},{"key":"2331_CR3","doi-asserted-by":"publisher","first-page":"2496","DOI":"10.1056\/NEJMoa1013343","volume":"364","author":"R Bejar","year":"2011","unstructured":"Bejar R et al (2011) Clinical effect of point mutations in myelodysplastic syndromes. N Engl J Med 364:2496\u20132506. doi: 10.1056\/NEJMoa1013343","journal-title":"N Engl J Med"},{"key":"2331_CR4","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1002\/1097-0142(20011015)92:8<1999::AID-CNCR1538>3.0.CO;2-B","volume":"92","author":"M Beran","year":"2001","unstructured":"Beran M et al (2001) High-dose chemotherapy in high-risk myelodysplastic syndrome: covariate-adjusted comparison of five regimens. Cancer 92:1999\u20132015","journal-title":"Cancer"},{"key":"2331_CR5","doi-asserted-by":"publisher","first-page":"3884","DOI":"10.1200\/JCO.2006.09.4169","volume":"25","author":"W Blum","year":"2007","unstructured":"Blum W et al (2007) Phase I study of decitabine alone or in combination with valproic acid in acute myeloid leukemia. J Clin Oncol 25:3884\u20133891. doi: 10.1200\/JCO.2006.09.4169","journal-title":"J Clin Oncol"},{"key":"2331_CR6","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1002\/gcc.21960","volume":"51","author":"M Brecqueville","year":"2012","unstructured":"Brecqueville M et al (2012) Mutation analysis of ASXL1, CBL, DNMT3A, IDH1, IDH2, JAK2, MPL, NF1, SF3B1, SUZ12, and TET2 in myeloproliferative neoplasms. Genes Chromosomes Cancer 51:743\u2013755. doi: 10.1002\/gcc.21960","journal-title":"Genes Chromosomes Cancer"},{"key":"2331_CR7","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1182\/blood-2005-10-4149","volume":"108","author":"BD Cheson","year":"2006","unstructured":"Cheson BD et al (2006) Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood 108:419\u2013425. doi: 10.1182\/blood-2005-10-4149","journal-title":"Blood"},{"key":"2331_CR8","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1038\/leu.2015.244","volume":"30","author":"N Daver","year":"2016","unstructured":"Daver N et al (2016) A phase II study of decitabine and gemtuzumab ozogamicin in newly diagnosed and relapsed acute myeloid leukemia and high-risk myelodysplastic syndrome. Leukemia 30:268\u2013273. doi: 10.1038\/leu.2015.244","journal-title":"Leukemia"},{"key":"2331_CR9","doi-asserted-by":"crossref","first-page":"6627","DOI":"10.7314\/APJCP.2015.16.15.6627","volume":"16","author":"S Gao","year":"2015","unstructured":"Gao S et al (2015) Decitabine in the treatment of acute myeloid leukemia and myelodysplastic syndromes, which combined with complex Karyotype respectively. Asian Pac J Cancer Prev 16:6627\u20136632","journal-title":"Asian Pac J Cancer Prev"},{"key":"2331_CR10","doi-asserted-by":"publisher","first-page":"3271","DOI":"10.1182\/blood-2006-03-009142","volume":"108","author":"G Garcia-Manero","year":"2006","unstructured":"Garcia-Manero G et al (2006) Phase 1\/2 study of the combination of 5-aza-2\u2032-deoxycytidine with valproic acid in patients with leukemia. Blood 108:3271\u20133279. doi: 10.1182\/blood-2006-03-009142","journal-title":"Blood"},{"key":"2331_CR11","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.leukres.2016.02.002","volume":"44","author":"S Geng","year":"2016","unstructured":"Geng S et al. (2016) Effects of the combination of decitabine and homoharringtonine in SKM-1 and Kg-1a cells. Leuk Res 44:17\u201324. doi: 10.1016\/j.leukres.2016.02.002","journal-title":"Leuk Res"},{"key":"2331_CR12","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1038\/ng.1031","volume":"44","author":"TA Graubert","year":"2011","unstructured":"Graubert TA et al (2011) Recurrent mutations in the U2AF1 splicing factor in myelodysplastic syndromes. Nat Genet 44:53\u201357. doi: 10.1038\/ng.1031","journal-title":"Nat Genet"},{"key":"2331_CR13","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1038\/ng.1031","volume":"44","author":"TA Graubert","year":"2012","unstructured":"Graubert TA et al (2012) Recurrent mutations in the U2AF1 splicing factor in myelodysplastic syndromes. Nat Genet 44:53\u201357. doi: 10.1038\/ng.1031","journal-title":"Nat Genet"},{"key":"2331_CR14","doi-asserted-by":"crossref","first-page":"30","DOI":"10.6004\/jnccn.2011.0005","volume":"9","author":"PL Greenberg","year":"2011","unstructured":"Greenberg PL et al. (2011) NCCN Clinical Practice Guidelines in Oncology: myelodysplastic syndromes J Natl Compr Cancer Netw JNCCN 9:30\u201356","journal-title":"J Natl Compr Cancer Netw JNCCN"},{"key":"2331_CR15","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1038\/leu.2013.336","volume":"28","author":"T Haferlach","year":"2014","unstructured":"Haferlach T et al (2014) Landscape of genetic lesions in 944 patients with myelodysplastic syndromes. Leukemia 28:241\u2013247. doi: 10.1038\/leu.2013.336","journal-title":"Leukemia"},{"key":"2331_CR16","doi-asserted-by":"publisher","first-page":"2250","DOI":"10.3109\/10428194.2010.524324","volume":"51","author":"M Iastrebner","year":"2010","unstructured":"Iastrebner M et al. (2010) Decitabine in myelodysplastic syndromes and chronic myelomonocytic leukemia: Argentinian\/South Korean multi-institutional clinical experience. Leuk Lymphoma 51:2250\u20132257. doi: 10.3109\/10428194.2010.524324","journal-title":"Leuk Lymphoma"},{"key":"2331_CR17","doi-asserted-by":"publisher","first-page":"33612","DOI":"10.18632\/oncotarget.5600","volume":"6","author":"X Jiang","year":"2015","unstructured":"Jiang X et al (2015) The hypomethylating agent decitabine prior to chemotherapy improves the therapy efficacy in refractory\/relapsed acute myeloid leukemia patients. Oncotarget 6:33612\u201333622. doi: 10.18632\/oncotarget.5600","journal-title":"Oncotarget"},{"key":"2331_CR18","doi-asserted-by":"publisher","first-page":"1794","DOI":"10.1002\/cncr.21792","volume":"106","author":"H Kantarjian","year":"2006","unstructured":"Kantarjian H et al (2006) Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer 106:1794\u20131803. doi: 10.1002\/cncr.21792","journal-title":"Cancer"},{"key":"2331_CR19","doi-asserted-by":"publisher","unstructured":"Kantarjian H et al (2007a) Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood 109:52\u201357. doi: 10.1182\/blood-2006-05-021162","DOI":"10.1182\/blood-2006-05-021162"},{"key":"2331_CR20","doi-asserted-by":"publisher","unstructured":"Kantarjian HM et al (2007b) Survival advantage with decitabine versus intensive chemotherapy in patients with higher risk myelodysplastic syndrome: comparison with historical experience. Cancer 109:1133\u20131137. doi: 10.1002\/cncr.22508","DOI":"10.1002\/cncr.22508"},{"key":"2331_CR21","doi-asserted-by":"publisher","unstructured":"Kantarjian HM et al (2007c) Update of the decitabine experience in higher risk myelodysplastic syndrome and analysis of prognostic factors associated with outcome. Cancer 109:265\u2013273. doi: 10.1002\/cncr.22376","DOI":"10.1002\/cncr.22376"},{"key":"2331_CR22","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1111\/bjh.13016","volume":"167","author":"M Kirschbaum","year":"2014","unstructured":"Kirschbaum M et al (2014) A phase 1 clinical trial of vorinostat in combination with decitabine in patients with acute myeloid leukaemia or myelodysplastic syndrome. Br J Haematol 167:185\u2013193. doi: 10.1111\/bjh.13016","journal-title":"Br J Haematol"},{"key":"2331_CR23","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1002\/cncr.22779","volume":"110","author":"S Knipp","year":"2007","unstructured":"Knipp S et al (2007) Intensive chemotherapy is not recommended for patients aged >60\u00a0years who have myelodysplastic syndromes or acute myeloid leukemia with high-risk karyotypes. Cancer 110:345\u2013352. doi: 10.1002\/cncr.22779","journal-title":". Cancer"},{"key":"2331_CR24","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1038\/leu.2010.52","volume":"24","author":"O Kosmider","year":"2010","unstructured":"Kosmider O et al (2010) Mutations of IDH1 and IDH2 genes in early and accelerated phases of myelodysplastic syndromes and MDS\/myeloproliferative neoplasms. Leukemia 24:1094\u20131096. doi: 10.1038\/leu.2010.52","journal-title":"Leukemia"},{"key":"2331_CR25","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.3324\/haematol.2011.046078","volume":"96","author":"JH Lee","year":"2011","unstructured":"Lee JH et al (2011) A prospective multicenter observational study of decitabine treatment in Korean patients with myelodysplastic syndrome. Haematologica 96:1441\u20131447. doi: 10.3324\/haematol.2011.046078","journal-title":"Haematologica"},{"key":"2331_CR26","doi-asserted-by":"publisher","first-page":"e87475","DOI":"10.1371\/journal.pone.0087475","volume":"9","author":"SM Leonard","year":"2014","unstructured":"Leonard SM, Perry T, Woodman CB, Kearns P (2014) Sequential treatment with cytarabine and decitabine has an increased anti-leukemia effect compared to cytarabine alone in xenograft models of childhood acute myeloid leukemia. PloS One 9:e87475. doi: 10.1371\/journal.pone.0087475","journal-title":"PloS One"},{"key":"2331_CR27","doi-asserted-by":"publisher","first-page":"1516","DOI":"10.1016\/j.leukres.2013.09.006","volume":"37","author":"X Li","year":"2013","unstructured":"Li X et al. (2013) Cytogenetic response based on revised IPSS cytogenetic risk stratification and minimal residual disease monitoring by FISH in MDS patients treated with low-dose decitabine. Leuk Res 37:1516\u20131521. doi: 10.1016\/j.leukres.2013.09.006","journal-title":"Leuk Res"},{"key":"2331_CR28","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1186\/1479-5876-12-167","volume":"12","author":"K Li","year":"2014","unstructured":"Li K et al. (2014) Sequential combination of decitabine and idarubicin synergistically enhances anti-leukemia effect followed by demethylating Wnt pathway inhibitor promoters and downregulating Wnt pathway nuclear target. J Transl Med 12:167. doi: 10.1186\/1479-5876-12-167","journal-title":"J Transl Med"},{"key":"2331_CR29","doi-asserted-by":"crossref","first-page":"6448","DOI":"10.18632\/oncotarget.3361","volume":"6","author":"J Li","year":"2015","unstructured":"Li J et al (2015) Efficacy and safety of decitabine in combination with G-CSF, low-dose cytarabine and aclarubicin in newly diagnosed elderly patients with acute myeloid leukemia. Oncotarget 6:6448\u20136458","journal-title":"Oncotarget"},{"key":"2331_CR30","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1046\/j.1365-2141.2001.02933.x","volume":"114","author":"M Lubbert","year":"2001","unstructured":"Lubbert M et al (2001) Cytogenetic responses in high-risk myelodysplastic syndrome following low-dose treatment with the DNA methylation inhibitor 5-aza-2\u2032-deoxycytidine. Br J Haematol 114:349\u2013357","journal-title":"Br J Haematol"},{"key":"2331_CR31","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1038\/ng.2696","volume":"45","author":"H Makishima","year":"2013","unstructured":"Makishima H et al (2013) Somatic SETBP1 mutations in myeloid malignancies. Nat Genet 45:942\u2013946. doi: 10.1038\/ng.2696","journal-title":"Nat Genet"},{"key":"2331_CR32","doi-asserted-by":"publisher","first-page":"6239","DOI":"10.1182\/blood-2011-09-377275","volume":"118","author":"L Malcovati","year":"2011","unstructured":"Malcovati L et al (2011) Clinical significance of SF3B1 mutations in myelodysplastic syndromes and myelodysplastic\/myeloproliferative neoplasms. Blood 118:6239\u20136246. doi: 10.1182\/blood-2011-09-377275","journal-title":"Blood"},{"key":"2331_CR33","doi-asserted-by":"publisher","first-page":"2943","DOI":"10.1182\/blood-2013-03-492884","volume":"122","author":"L Malcovati","year":"2013","unstructured":"Malcovati L et al (2013) Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet. Blood 122:2943\u20132964. doi: 10.1182\/blood-2013-03-492884","journal-title":"Blood"},{"key":"2331_CR34","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1182\/blood-2014-03-560227","volume":"124","author":"L Malcovati","year":"2014","unstructured":"Malcovati L et al (2014) Driver somatic mutations identify distinct disease entities within myeloid neoplasms with myelodysplasia. Blood 124:1513\u20131521. doi: 10.1182\/blood-2014-03-560227","journal-title":"Blood"},{"key":"2331_CR35","doi-asserted-by":"publisher","first-page":"1839","DOI":"10.1111\/j.1349-7006.2012.02386.x","volume":"103","author":"Y Oki","year":"2012","unstructured":"Oki Y et al (2012) Phase I\/II study of decitabine in patients with myelodysplastic syndrome: a multi-center study in Japan. Cancer Sci 103:1839\u20131847. doi: 10.1111\/j.1349-7006.2012.02386.x","journal-title":"Cancer Sci"},{"key":"2331_CR36","doi-asserted-by":"publisher","first-page":"1384","DOI":"10.1056\/NEJMoa1103283","volume":"365","author":"E Papaemmanuil","year":"2011","unstructured":"Papaemmanuil E et al (2011) Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts. N Engl J Med 365:1384\u20131395. doi: 10.1056\/NEJMoa1103283","journal-title":"N Engl J Med"},{"key":"2331_CR37","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.1038\/leu.2010.98","volume":"24","author":"A Pardanani","year":"2010","unstructured":"Pardanani A et al (2010) Recurrent IDH mutations in high-risk myelodysplastic syndrome or acute myeloid leukemia with isolated del(5q). Leukemia 24:1370\u20131372. doi: 10.1038\/leu.2010.98","journal-title":"Leukemia"},{"key":"2331_CR38","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1182\/blood-2011-09-377994","volume":"119","author":"MM Patnaik","year":"2012","unstructured":"Patnaik MM et al (2012) SF3B1 mutations are prevalent in myelodysplastic syndromes with ring sideroblasts but do not hold independent prognostic value. Blood 119:569\u2013572. doi: 10.1182\/blood-2011-09-377994","journal-title":"Blood"},{"key":"2331_CR39","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1002\/ajh.23373","volume":"88","author":"MM Patnaik","year":"2013","unstructured":"Patnaik MM et al (2013) Spliceosome mutations involving SRSF2, SF3B1, and U2AF35 in chronic myelomonocytic leukemia: prevalence, clinical correlates, and prognostic relevance. Am J Hematol 88:201\u2013206. doi: 10.1002\/ajh.23373","journal-title":"Am J Hematol"},{"key":"2331_CR40","doi-asserted-by":"publisher","first-page":"6904","DOI":"10.1182\/blood-2011-08-373159","volume":"118","author":"D Rossi","year":"2011","unstructured":"Rossi D et al (2011) Mutations of the SF3B1 splicing factor in chronic lymphocytic leukemia: association with progression and fludarabine-refractoriness. Blood 118:6904\u20136908. doi: 10.1182\/blood-2011-08-373159","journal-title":"Blood"},{"key":"2331_CR41","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.1182\/blood-2010-11-320093","volume":"118","author":"JM Scandura","year":"2011","unstructured":"Scandura JM et al (2011) Phase 1 study of epigenetic priming with decitabine prior to standard induction chemotherapy for patients with AML. Blood 118:1472\u20131480. doi: 10.1182\/blood-2010-11-320093","journal-title":"Blood"},{"key":"2331_CR42","doi-asserted-by":"publisher","first-page":"1879","DOI":"10.1007\/s00277-012-1550-y","volume":"91","author":"LX Song","year":"2012","unstructured":"Song LX et al (2012) Clinical outcome of treatment with a combined regimen of decitabine and aclacinomycin\/cytarabine for patients with refractory acute myeloid leukemia. Ann Hematol 91:1879\u20131886. doi: 10.1007\/s00277-012-1550-y","journal-title":"Ann Hematol"},{"key":"2331_CR43","doi-asserted-by":"publisher","first-page":"3842","DOI":"10.1200\/JCO.2008.19.6550","volume":"27","author":"DP Steensma","year":"2009","unstructured":"Steensma DP et al (2009) Multicenter study of decitabine administered daily for 5 days every 4 weeks to adults with myelodysplastic syndromes: the alternative dosing for outpatient treatment (ADOPT) trial. J Clin Oncol 27:3842\u20133848. doi: 10.1200\/JCO.2008.19.6550","journal-title":"J Clin Oncol"},{"key":"2331_CR44","doi-asserted-by":"publisher","first-page":"3578","DOI":"10.1182\/blood-2011-12-399337","volume":"119","author":"F Thol","year":"2012","unstructured":"Thol F et al (2012) Frequency and prognostic impact of mutations in SRSF2, U2AF1, and ZRSR2 in patients with myelodysplastic syndromes. Blood 119:3578\u20133584. doi: 10.1182\/blood-2011-12-399337","journal-title":"Blood"},{"key":"2331_CR45","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/S1053-4296(03)00031-6","volume":"13","author":"A Trotti","year":"2003","unstructured":"Trotti A et al (2003) CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol 13:176\u2013181. doi: 10.1016\/S1053-4296(03)00031-6","journal-title":"Semin Radiat Oncol"},{"key":"2331_CR46","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1182\/blood-2009-03-209262","volume":"114","author":"JW Vardiman","year":"2009","unstructured":"Vardiman JW et al (2009) The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 114:937\u2013951. doi: 10.1182\/blood-2009-03-209262","journal-title":"Blood"},{"key":"2331_CR47","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1038\/leu.2011.44","volume":"25","author":"MJ Walter","year":"2011","unstructured":"Walter MJ et al (2011) Recurrent DNMT3A mutations in patients with myelodysplastic syndromes. Leukemia 25:1153\u20131158. doi: 10.1038\/leu.2011.44","journal-title":"Leukemia"},{"key":"2331_CR48","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.3109\/10428194.2015.1096351","volume":"57","author":"L Wu","year":"2016","unstructured":"Wu L et al. (2016) Efficacy and toxicity of decitabine versus CHG regimen (low-dose cytarabine, homoharringtonine and granulocyte colony-stimulating factor) in patients with higher risk myelodysplastic syndrome: a retrospective study. Leuk Lymphoma 57:1367\u20131374. doi: 10.3109\/10428194.2015.1096351","journal-title":"Leuk Lymphoma"},{"key":"2331_CR49","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1056\/NEJMoa0808710","volume":"360","author":"H Yan","year":"2009","unstructured":"Yan H et al (2009) IDH1 and IDH2 mutations in gliomas. N Engl J Med 360:765\u2013773. doi: 10.1056\/NEJMoa0808710","journal-title":"N Engl J Med"},{"key":"2331_CR50","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1016\/j.leukres.2004.11.022","volume":"29","author":"H Yang","year":"2005","unstructured":"Yang H, Hoshino K, Sanchez-Gonzalez B, Kantarjian H, Garcia-Manero G (2005) Antileukemia activity of the combination of 5-aza-2\u2032-deoxycytidine with valproic acid. Leuk Res 29:739\u2013748. doi: 10.1016\/j.leukres.2004.11.022","journal-title":"Leuk Res"},{"key":"2331_CR51","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.3109\/10428194.2015.1091931","volume":"57","author":"XN Ye","year":"2016","unstructured":"Ye XN et al. (2016) Epigenetic priming with decitabine followed by low-dose idarubicin\/cytarabine has an increased anti-leukemic effect compared to traditional chemotherapy in high-risk myeloid neoplasms. Leuk Lymphoma 57:1311\u20131318. doi: 10.3109\/10428194.2015.1091931","journal-title":"Leuk Lymphoma"},{"key":"2331_CR52","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1016\/j.leukres.2015.01.014","volume":"39","author":"WH Zhao","year":"2015","unstructured":"Zhao WH, Zeng QC, Huang BT, Li BS, Chen RL (2015) Decitabine plus thalidomide yields more sustained survival rates than decitabine monotherapy for risk-tailored elderly patients with myelodysplastic syndrome. Leuk Res 39:424\u2013428. doi: 10.1016\/j.leukres.2015.01.014","journal-title":"Leuk Res"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-016-2331-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00432-016-2331-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-016-2331-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,17]],"date-time":"2020-05-17T13:59:30Z","timestamp":1589723970000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00432-016-2331-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1,20]]},"references-count":52,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2017,5]]}},"alternative-id":["2331"],"URL":"https:\/\/doi.org\/10.1007\/s00432-016-2331-0","relation":{},"ISSN":["0171-5216","1432-1335"],"issn-type":[{"value":"0171-5216","type":"print"},{"value":"1432-1335","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,1,20]]}}}